Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
तुलना करने के लिए मीट्रिक्स | GERN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGERNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −11.9x | −2.6x | −0.5x | |
PEG अनुपात | −0.22 | 0.02 | 0.00 | |
क़ीमत/बुक | 4.4x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.4x | 10.0x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 158.1% | 97.3% | 45.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 21.3% | 6.4% | अनलॉक करें |